Compositions for regenerating defective or absent myocardium
US-9199001-B2 · Dec 1, 2015 · US
Pharmaceutical compositions including a portion of the C-terminus of FGF23
US9272017B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9272017-B2 |
| Application number | US-201313763301-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2013 |
| Priority date | Oct 30, 2009 |
| Publication date | Mar 1, 2016 |
| Grant date | Mar 1, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a pharmaceuticalm composition comprising a peptide comprising at least a portion corresponding to the C-terminus of FGF23 and an additive selected from the group consisting of vitamin D and a vitamin D receptor agonist.
First claim
Opening claim text (preview).
What is claimed: 1. A pharmaceutical composition comprising: a peptide comprising at least a portion corresponding to the C-terminus of FGF23, wherein the portion corresponding to the C-terminus of FGF23 consists of the amino acid sequence of SEQ ID NO:12 and an additive, wherein the additive is a vitamin D receptor agonist and is formulated in combination with said peptide for simultaneous administration. 2. The pharmaceutical composition according to claim 1 , wherein the peptide consists of SEQ ID NO:12. 3. The pharmaceutical composition according to claim 1 further comprising a pharmaceutically acceptable carrier. 4. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of a tablet, capsule, powder, solution, suspension, or emulsion. 5. The pharmaceutical composition according to claim 1 , wherein the composition is formulated for administration to a subject orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes. 6. The pharmaceutical composition according to claim 1 , wherein the additive is vitamin D.
Assignees
Inventors
Classifications
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
from mammals · CPC title
involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title
Systems specially adapted for particular applications · CPC title
- A61K38/1825Primary
Fibroblast growth factor [FGF] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9272017B2 cover?
- The present invention is directed to a pharmaceuticalm composition comprising a peptide comprising at least a portion corresponding to the C-terminus of FGF23 and an additive selected from the group consisting of vitamin D and a vitamin D receptor agonist.
- Who is the assignee on this patent?
- Univ New York
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1825. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).